iRhythm’s Chief Accounting Officer Sells 280 Shares Under 10b5‑1 Plan Amid Broad Insider Exits: What It Means for Investors

Insider Selling by the Chief Accounting Officer

On February 24, 2026 the Chief Accounting Officer of iRhythm Holdings, Marc Wade, sold 280 shares of the company’s common stock under a Rule 10b5‑1 trading plan. The sale, executed at a price of $140.91, left Wade’s post‑transaction holdings at 10,601 shares. The transaction was filed as a Form 4 and reported within the required 10‑day window, indicating compliance with regulatory timing requirements.

What the Sale Means for Investors

Wade’s sale is modest relative to the size of his overall stake and to the 10‑day reporting period, suggesting it may be a routine execution of a pre‑arranged plan rather than a reaction to material information. However, the fact that Wade executed a sell order just as the share price dipped slightly from its 2026‑02‑23 close of $137.10 to $140.91 could be interpreted by market watchers as a neutral signal. In the broader context, the company’s recent quarterly performance, a 52‑week low of $92.52, and a negative price‑earnings ratio of –103.09 underline a valuation gap that may attract value‑oriented investors. A modest insider sale amid a broader decline could be seen as a “buy‑the‑dip” tactic for long‑term holders.

Insider Activity Across the Board

In the same filing window, other senior executives have also moved their positions: EVP Mervin Smith sold 732 shares, and several senior officers (e.g., CFO Daniel Wilson and CEO Quentin Blackford) completed sizable sell orders in August 2025. The pattern of incremental sales by multiple insiders may indicate a strategic rebalancing of personal portfolios or a shift toward more liquid assets, possibly in anticipation of upcoming corporate events (e.g., product launches or regulatory approvals). Investors should watch for any correlation between insider exits and forthcoming earnings releases or product milestones, as such events can amplify price volatility.

Marc Wade’s Historical Trading Profile

Wade’s past transactions reveal a consistent, low‑volume trading strategy. Since the start of 2025, he has completed only two trades: a buy of 2 shares on November 28, 2025, and a sell of 226 shares on August 11, 2025. These trades were executed at $119.55 and $158.93 respectively, leaving his holdings around 10,880 shares. The small trade sizes and the use of a Rule 10b5‑1 plan suggest Wade prioritizes compliance and long‑term ownership rather than opportunistic trading. His disciplined approach contrasts with the more aggressive sales by other executives and may reassure investors that Wade is not reacting to negative insider sentiment.

Outlook for iRhythm Holdings

The company’s fundamentals—particularly its focus on cardiac rhythm monitoring and growing product pipeline—provide a solid long‑term growth narrative. Yet the steep decline in its share price, the negative P/E ratio, and the mix of analyst ratings (ranging from strong buy to sell) reflect heightened uncertainty. Insider transactions, while modest, offer a glimpse into executive confidence but should be weighed against broader market dynamics, including sector volatility and regulatory developments in medical device approvals. For investors, the current insider activity signals no immediate red flags, but vigilance is warranted as iRhythm approaches its next earnings cycle and potential product launches.